Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Proportion of patients receiving platelets · People with chronic bone marrow failure
Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion reaction · People with chronic bone marrow failure
1 finding from 1 review
Thromboembolism · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug reactions · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).
1 finding from 1 review
Number of red cell transfusions per participant · People with chronic bone marrow failure
1 finding from 1 review
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in incidence of severe infections (Grade III or IV) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found